Supporting continuous enteral feeding

FIELD: medicine.

SUBSTANCE: given invention is presented by a group of inventions which refer to medicine, namely to gastroenterology, particularly to methods and a composition for supporting continuous enteral feeding. The methods and composition for enteral nutritional support at least once a day applicable continuously involve a certain optimal composition in 100 kcal of a product of proteins, carbohydrates, lipids, vitamins, salts and microelements.

EFFECT: methods and composition provide continuously applicable enteral feeding in the patients with normal metabolism, but unable eating normally.

2 ex, 31 cl

 

The present invention relates to nutrition. More specifically, the present invention relates to therapeutic feeding.

The level of technology

The result of a number of diseases, lesions and complications is the fact that patients may be unable to obtain necessary food, taking food by mouth, for example, eating food. In this regard, the known methods of providing therapeutic feeding or interline or parenterally. We developed many different formulations to provide such a therapeutic feeding.

Even in terms of standard products for enteral nutrition, these products are intended for short-term use, usually from 10 to 24 days. These products typically provide essential nutritional components to supply the necessary power with acute pathology of the patients during their stay in hospital. Although these products are suitable for such short-term use during their development objectives were not achieving the required suitability for the nutrition of patients over a long period of time. With the development of medicine, leading to increased life expectancy and the development of more effective treatments, a number of individuals could benefit from products intended to ensure that food is positive enteral nutrition.

The invention

The present invention provides methods and compositions for providing enteral feeding, suitable for use in a long time. More specifically, the present invention provides methods and compositions for ensuring suitable for use in a long time enteral feeding for patients with normal metabolism, unable to eat a normal diet.

To this end, in one embodiment is provided a method of providing patient is suitable for use in a long time probe power, including the stages of supply through the tube at least once a day in need of long-term enteral nutrition patient product for enteral nutrition containing per 100 kcal of product: protein source, a source of carbohydrates, a source of lipids, from 100 to 200 mg of sodium, 25 to 250 mg of potassium, more than 50 mg of calcium, phosphorus less than 150 mg, magnesium - at least 15 mg, chlorine is at least 100 mg- iron of 0.4 to 1.5 mg, zinc - from 0.4 to 2.0 mg, copper - from 0.08 to 0.4 mg fluoride from 0 to 0.15 mg, chromium from 2.0 to 10.0 mcg, molybdenum from 2.0 to 14.0 mg, selenium - from 3.0 to 9.0 mcg, manganese, from 0.1 to 0.4 mg, iodine - from 7.0 to 15.0 ág, vitamin a - 100 to 500 ME, vitamin D is from 0.5 to 2.5 mg, vitamin E - from 1.5 to 4.0 mg, vitamin K is more than 4.0 µg, vitamin C - more than 4.0 mg, vitamin B1 - than 0.06 mg, vitamin B2 - Bo is her 0.07 mg, vitamin B3 is from 0.7 to 3.5 mg, vitamin B5 from 0.2 to 2.0 mg, vitamin B6 - from 0.1 to 0.7 mg, vitamin B8 is at least 1.0 microgram, vitamin B9 - at least to 12.0 µg vitamin B12 from 0.1 to 1.0 μg.

Product for enteral nutrition may, in one embodiment contain additional components. For example, at least 30 mg of choline per 100 kcal of the product, at least 4.0 mg of taurine per 100 kcal of the product and/or at least 3.0 mg of carnitine per 100 kcal of the product.

In one embodiment of the method, the protein source provides from 10 to 18% of the energy value of the product. The protein source can be selected from the group consisting of casein, whey and soy. In addition, the protein may be native or partially hydrolyzed. As for the source of carbohydrates, it can provide from 40 to 65% of the energy value of the product. When the content of saturated fatty acids is not higher than 1.1 g/100 kcal of a source of lipids can provide from 25 to 40% of the energy value of the product; the composition comprises between 0.3 and 1.1 g of linoleic acid per 100 kcal, the composition contains at least 0.06 g of linolenic acid per 100 kcal and has the value of the ratio n6: n3 between 2 and 7. The product may also contain a source of dietary fiber, providing its content of at least 10 g/l Cellulose may contain insoluble fiber and soluble fiber. For example, nerist the action of the fiber may be, at least 25% of the total number of fibers source. The fiber may contain polysaccharides of soybean and the outer fiber of the peas.

If desired, the composition may contain a prebiotic. In one embodiment, the prebiotic may be inulin. In another embodiment, the product has a density of from 0.8 to 1.4 kcal/ml

In addition, in one embodiment of the present invention provides a method of feeding a patient, comprising the steps of providing long-term needs nutrition to the patient at least once a day product for enteral feeding, comprising: a source of protein, providing from 10 to 18% of the energy value of the product, a source of carbohydrates, providing 40 to 65% of the energy value of the product, a source of lipids, providing from 25 to 40% of the energy value of the product, a source of dietary fiber in the amount of at least 10 g/l, containing soluble and insoluble fiber, sodium - 100 up to 200 mg, potassium - from 25 to 250 mg, calcium - more than 50 mg, phosphorus - less than 150 mg, magnesium - at least 15 mg, chlorine is at least 100 mg, iron 0.4 to 1.5 mg, zinc - from 0.4 to 2.0 mg, copper - from 0.08 to 0.4 mg fluoride from 0 to 0.15 mg, chromium from 2.0 to 10.0 mcg, molybdenum from 2.0 to 14.0 mg, selenium - from 3.0 to 9.0 mcg, manganese, from 0.1 to 0.4 mg, iodine-from 7.0 to 15.0 mg, lycopene is at least 0.2 mg, beta-carotene - at IU the e 0.1 mg, vitamin a is from 100 to 500 ME, vitamin D is from 0.5 to 2.5 mg, vitamin E - from 1.5 to 4.0 mg, vitamin K - more than 6.0 micrograms, vitamin C - more than 4.0 mg, vitamin B1 - than 0.06 mg, vitamin B2 - more than 0.07 mg, vitamin B3 from 0.7 to 3.5 mg, vitamin B5 from 0.2 to 2.0 mg, vitamin B6 - from 0.1 to 0.7 mg, vitamin B8 is at least 1.0 microgram, vitamin B9 - at least to 12.0 µg and vitamin B12 is from 0.1 to 1.0 μg.

Still further, in one embodiment of the present invention provides a product for enteral nutrition containing: sodium - 100 to 200 mg, potassium - from 25 to 250 mg, calcium - more than 50 mg, phosphorus - less than 150 mg, magnesium - at least 15 mg, chlorine is at least 100 mg, iron 0.4 to 1.5 mg, zinc - from 0.4 to 2.0 mg, copper - from 0.08 to 0.4 mg fluoride from 0 to 0.15 mg, chromium from 2.0 to 10.0 μg, molybdenum from 2.0 to 14.0 mg, selenium - from 3.0 to 9.0 mcg, manganese, from 0.1 to 0.4 mg, iodine - from 7.0 to 15.0 ág, vitamin a - 100 to 500 ME, vitamin D is from 0.5 to 2.5 mg, vitamin E - from 1.5 to 4.0 mg, vitamin K - more than 6.0 micrograms, vitamin C - more than 4.0 mg, vitamin B1 - than 0.06 mg, vitamin B2 - more than 0.07 mg, vitamin B3 from 0.7 to 3.5 mg, vitamin B5 from 0.2 to 2.0 mg, vitamin B6 - from 0.1 to 0.7 mg, vitamin B8 is at least 1.0 microgram, vitamin B9 - at least to 12.0 µg, vitamin B12 is from 0.1 to 1.0 µg lycopene is at least 0.2 mg, beta-carotene, which is at least 0.1 mg, protein source providing from 10 to 18% of the energy value of the product, a source of carbohydrate that provides from 40 to 65% of Energeticheskaya product, the source of lipids, providing from 25 to 40% of the energy value of the product, and a source of dietary fiber in the amount of at least 10 g/l, which provides both soluble and insoluble fiber.

As noted above, the product for enteral nutrition may also contain at least 30 mg of choline, at least 5.0 mg of taurine and at least 3.0 mg carnitine (each per 100 kcal of the product).

Still further, in one embodiment of the present invention provides a method of presenting food to a patient, comprising the steps of introducing in a long time in need of maintenance therapy to a patient at least once a day product, comprising: at least one of lycopene, lutein, β-carotene, β-cryptoxanthin, polyphenol, protein source, a source of carbohydrate, a source of fiber and a source of lipids.

In one embodiment of polyphenols selected from the group consisting of catechin, isoflavones and quercetin.

One of the advantages of the present invention is to provide improved products for enteral nutrition.

Another advantage of the present invention is to provide products for enteral nutrition, intended for use in a long time.

In addition, one of the advantages of the present invention comprised the t in providing compositions to provide the needy in this patient power suitable for use in a long time.

Moreover, one of the advantages of the present invention is to provide methods of providing the needy in this patient power, suitable for use in a long time.

It also describes additional characteristics and advantages will be apparent from the following detailed description.

Disclosure of inventions

The present invention relates to therapeutic feeding. More specifically, the present invention relates to securing suitable for use in a long time, fed through a tube power need patients. For the purposes of the present invention, the expression "suitable for use in a long time" means more than one month (30 days). For the purposes of the present invention, the term "supplied through the probe" refers to a product provided to the patient through the feeding tube that is placed inside the part of the digestive tract of the patient, for example, through a percutaneous endoscopic gastrostomy or nasogastric feeding tube. At the same time applicants applying for the patent, entitled "Methods of ensuring suitable for use in long supply", which discloses suitable for different application is for a long time products for enteral nutrition and the ways and based on this business techniques (treatment), the disclosure of which is incorporated herein by reference.

Suitable for use in a long time, supplied through the probe nutritious product is intended for those on maintenance therapy patients. For the purposes of the present invention "are on maintenance therapy, the patient" refers to an adult patient under the age of sixty-five years, is unable to receive power through a normal diet, but with normal metabolism (i.e. not suffering from metabolic disorders). Such a patient may have to postpone surgery for cancer of the head or neck leading to the loss of part of the digestive tract or to inability to swallow, could receive a neck damage that led him or her to inability to swallow, or could become unable to swallow the result of neurological damage caused, for example, stroke. For the purposes of the present invention, the term "normal diet" implies obtaining at least essentially all of the power in use, i.e. with the use of the mouth, without the use of any feeding tubes or parenteral feeding.

The present invention provides methods and products, which are compared with the standard the products for enteral nutrition is optimized and/or improved to ensure the possibility of their application in a long time, especially for serving nutritious meals and snacks are on maintenance therapy to patients. For the purposes of the present invention the term "standard product for enteral nutrition" refers to products which are not advertised or promoted as products that are intended to use it for a long time. A number of such products available, for example, companies Nestle Clinical Nutrition, Abbott, Novartis, Numico and Fresenius. In one embodiment these products are intended for patients receiving outpatient treatment. The provision of such products may be, for example, nursing home, out-of-care centers for the sick or even at home by the patient. Preferably these nutritional products are Packed in plastic bags. In this area known a number of such packages, for example, 500 ml, 1000 ml and 1500 ml it Should be noted that to accommodate the nutritional product may be used any suitable container. Typically, products are introduced so that the patient received per day 1500 ml, although specialists in this field it is clear that the possible change in the quantity of input product.

Because the formulation is suitable for use in a long time product for enteral feeding according to the present invention is provided to support the Onan is intended for use as any special, qualitative or quantitative additions. Normal patients are stable with normal metabolism, healthy, except that they are to meet the nutritional needs required enteral nutrition patients. Thus, these patients may suffer from a number of violations, including violations of swallowing function of various etiologies, in particular, which is the result of surgery for cancer of the ear/nose/throat, as well as patients suffering from acute cerebral vascular disorders.

One of the objectives of this recipe is to optimize the condition of the metabolism and stability in the receiving enteral nutrition for a long time patients. Providing not only the necessary macronutrients, but also micronutrients that contribute to the provision of, for example, antioxidant status, the recipe may support the metabolism of the body in a condition comparable to the condition of a fully healthy individual of the same age, eating a balanced diet. Thus, the present invention provides a method of improving metabolic stability in patients receiving long time enteral nutrition.

Although in one preferred embodiment of the formulation of prednaznache the Xia to provide the necessary nutrients, minerals and vitamins thus, in order to meet state standards (defined below), there are some exceptions in regard to these recommendations. In this respect preferably used higher amounts of calcium. In one embodiment of calcium is preferably used at least 33% more. One reason for this increase is that such patients have reduced physical activity. Moreover, preferably provided excessive amounts of vitamin D. In one preferred embodiment is provided by at least 150% more vitamin D than is required in accordance with at least some of the state regulations. Because of their reduced mobility of these patients are exposed to less sunlight and therefore, they have weakened the endogenous synthesis of this vitamin. It is expected that this increased introduction of calcium and vitamin D should support the maintenance of bone tissue. In addition, in the formulation of one embodiment of the introduction of iron corresponds to the standard state regulations against women. Usually they are much higher than for men. The idea is to avoid recurrence of iron deficiency anemia, which predisposed women.

The protein source preferably both of the accounts for from 10 to 18% of the energy value of the product. Can be used any sources of high quality protein, or their mixture. Examples include casein, whey and soy protein. Proteins can be native or partially gidrolizovannykh. If desirable, can be added free amino acids. In one embodiment uses a mixture of 50% Caseinate and 50% soy. Preferably the protein source is derived from a mixture of casein and soy protein, enabling a balanced introduction amino acids.

The source of carbohydrates is preferably from 40 to 65% of the energy value of the product. Can be any carbohydrate or mixture of carbohydrates. Examples include starches, maltodextrins, sucrose and mixtures thereof. In one embodiment uses 100% of maltodextrins.

The source of carbohydrates is preferably from 25 to 40% of the energy value of the product. May be provided with any suitable mixture of dietary lipids, including saturated fatty acids (SFA), monounsaturated fatty acids (MUFA), polyunsaturated fatty acids (PUFA) and triglycerides with a molecular chain of medium length (MCT). Saturated fatty acids are preferably present in quantities of less than 1.1 g/100 kcal. Preferably the composition contains between 0.3 and 1.1 g of linoleic acid (or its higher derivatives) per 100 kcal. The composition may contain at least 0.06 g linolenic to the slots or higher derivatives per 100 kcal. The ratio of n6:n3 is preferably from 2 to 7.

Preferably the composition has an energy density of from 0.80 to 1.4 kcal/ml

The value of introducing fiber in the formulation of the present invention is preferably high. In this patient population often higher. Preferably the composition contains at least 10 g/l of cellulose. Can be any suitable fiber or mixture of fibers. Examples of insoluble fibers are polysaccharides of soybean, the outer fiber of the peas. Examples of soluble fibers are Arabian gum, pectin, inulin and guar gum. In most cases, preferred is a mixture of soluble and insoluble fibers. Additionally, there may be included prebiotic fiber. A prebiotic is defined as neoslavery component of the food product, which beneficially affects the host organism by selectively stimulating the growth and/or activity of one or a limited number of bacterial species in the colon, thereby improving the health status of the host. Examples of prebiotic fibers include Arabian gum and fructo-oligosaccharides, such as inulin and hydrolyzed inulin. In one embodiment applies a mixture of 50% outer fiber peas, 37% of the inner pea fiber and 13% of prebiotic fiber (and Alina and hydrolyzed inulin) at a concentration of 16.7 g/L. This corresponds to a mixture of 66% insoluble fiber and 34% soluble fiber (including prebiotic fiber).

In one embodiment the nutritional products are specially designed so that they could provide a complete, usable for a long period of time, the power and try to provide the same macro - and micronutrients, which were swallowed a healthy person eating a balanced diet. So recipes in one embodiment reproduce that here referred to as "5-8 a day." For the purposes of the present invention, the term "5-8 per day" refers to the state, addressed to consumers, recommendations to eat five to eight servings of fruits and vegetables per day. Thus, in one embodiment the products are designed in such a way that they are to the extent possible, play a normal diet, preferably absorbed by individuals who do not require enteral feeding, through the provision of micronutrients and phytonutrients found in fruits and vegetables. In one embodiment of the present invention provides a method for developing suitable for use in a long time products for enteral nutrition, based on trying to play recommendations 5-8 a day." By providing that the CSOs nutritional product may support the antioxidant status of the patient, and the state of metabolism. The goal is to bring these patients into the state, most comparable to a totally healthy individual of the same age, eating a balanced diet.

It was found that the phytonutrients provide the following characteristics: antioxidant, anti-inflammatory properties, the ability to detoxification, protection against cancer, atherosclerosis prevention, mitigation metabolic syndrome and prevention of bone loss. To provide the necessary phytonutrients compositions of the present invention may include one or more carotenoids, such as lycopene (tomato), β-carotene (carrot, spinach, tomato), lutein (spinach), β-cryptoxanthin, vitamins, such as mixed Tocopherols (oil and nuts) and vitamin C (orange), and polyphenols, such as catechins (green tea).

Preferred products include food components required to provide the patient with adequate nutrition on a long term basis. In this regard, the products include, along with other possible ingredients: proteins, carbohydrates, fats, vitamins and minerals. In one embodiment, the products are essentially, if not completely correspond to at least some of the state regulations. For the purposes from the retene "state regulations" means any recommendations of any of the following governments: USA, basically USRDA (the U.S. recommended daily allowance), Germany, mainly recommended in Germany, daily allowance, and France, mainly recommended in France daily norms. In one embodiment the nutritional product meets or exceeds at least one of the state standards.

As an example and not as a limitation, we will show some examples of the present invention.

Example No. 1
The embodiment of the support of 1500 mlThe embodiment 100 ml
Calorieskcal1875125
Proteing624,1
Calcium Caseinateg31to 2.06
Soyg31to 2.06
Carbohydratesg25216,8
Maltodextrinsg23715,8
Carbohydrates from other sourcesg151,0
Fiberg231,52
Insoluble%6666
Instant%3434
Lipidsg724,8
SFAg110,73
MUFAg432,9
PUFAg110,73
Linoleic acid (n-6)g8,40,56
α-Linoleic KIS the PTA (n-3) g1,60,11
The ratio of ω6/ω35,25,2
Mineral substances and microelements
Sodiummg2400160
Potassiummg2445163
Calciummg129086
Phosphorusmg85557
Magnesiummg40527
Chlorinemg3225215
Ironmg181,2
Zinc mg120,78
Coppermg20,13
Fluoridemg1,40,09
Chromemcg1057,0
Molybdenummcg986,5
Seleniummcg81of 5.4
Manganesemg4,40,29
Iodinemcg16511
Vitamins
Vitamin a, totalME4500300
Vitamin Dmcg20 1,3
Vitamin EME483,2
Vitamin Kmcg1057,0
Vitamin Cmg180to 12.0
Vitamin B1 (thiamine)mg2,00,13
Vitamin B2 (Riboflavin)mg1,70,11
Vitamin B3-PP (Niacin)mg231,50
Vitamin B5 (Pantothenic acid)mg9,50,63
Vitamin B6 (pyridoxine)mg2,30,15
Vitamin B8 (Biotin)mcg57the 3.8
Vitamin B9 (folic acid) mcg45030
Vitamin b 12mcgthe 5.70,38
Other
Cholinemg81054
Taurinemg81of 5.4
Carnitinemg15010
Beta-carotene (carrots)mgthe 3.80,25
Lycopene (tomatoes)mg5,90,39

Example # 2

The embodiment of the support mlRange 100 kcalThe embodiment 100 ml
Calorieskcal18750,8-1,kcal/ml125
Proteing6210-18% of the total supplying energy to birds, native or partially hydrolyzed4,1
Calcium Caseinateg31to 2.06
Soyg31to 2.06
Carbohydratesg25240-65% of total16,8
of supplying energy to birds
Maltodextrinsg23715,8
Carbohydrates from other sourcesg5 1,0
Fiberg23>10 g/l1,5
Insoluble%6666
Instant%3434
Lipidsg7225-40% of total4,8
of supplying energy to birds
SFAg11saturated fats (without ITC)<10% of the total
of supplying energy to birds; or <1,11 g/cal
0,73
MUFAg432,9
PUFAg 110,73
Linoleic acid (n-6)g8,43-10% of the total supplying energy to birds of linoleic acid or higher ω6 derivatives or 0.33-1,11 g/100 kcal0,56
α-Linoleic acid (n-3)g1,6>0.6% of the total supplying energy to birds or >0.06 g/100 kcal0,11
The ratio of ω6/ω35,22-75,2
Mineral substances and microelements
Sodiummg2400100-200160
Potassiummg244525-250163
Calciummg1290 At least 50, preferably 50-300 g86
Phosphorusmg855<150 g, preferably 40-8057
Magnesiummg405At least 15, preferably 15-3527
Chlorinemg3225At least 100, preferably 150-250215
Ironmg180,4-1,51,2
Zincmg120,4-2,00,78
Coppermg20,08-0,40,13
Fluoridemg1,4<0,150,09
Chrome mcg1052-107,0
Molybdenummcg982-146,5
Seleniummcg813-9of 5.4
Manganesemcg4,4of 0.1-0.40,29
Iodinemcg1657-1511
Vitamins
Vitamin a, totalME4500100-500, including β-carotene300
Vitamin Dmcg200,5-2,51,3
Vitamin EIU 482,2-63,2
Vitamin Kmcg105More than 4, preferably 6-157,0
Vitamin Cmg180More than 4to 12.0
Vitamin B1 (thiamine)mg2,0Than 0.06, preferably 0,06-0,40,13
Vitamin B2 (Riboflavin)mg1,7More than 0.070,11
Vitamin B3-PP (Niacin)mg230,7-3,51,5
Vitamin B5 (Pantothenic acid)mg9,50,2-2,00,63
Vitamin B6 (pyridoxine)mg2,30,1-0,70,15
Vitamin B8 (Biotin)mcg57At least 1the 3.8
Vitamin B9 (folic acid)mcg450At least 1230
Vitamin B12mcgthe 5.70,1-10,38
Other
Cholinemg810In the presence of >3054
Taurinemg81In the presence of >4of 5.4
Carnitinemg150In the presence of >310
Beta-carotene (carrots)mg the 3.8>0,10,25
Lycopene (tomatoes)mg5,9>0,20,39

In accordance with the methods of the claimed invention taken as an example, any of the formulations of Examples 1 and 2 can be entered on a long term basis, at least once a day to the needy in the nutrition of the patient who can't eat normal diet, as long as it is necessary.

It should be understood that the specialists in this area is evident the possibility of introducing various changes and modifications described in this preferred embodiment. Such changes and modifications may be made without departure from the essence and scope of the present invention and without diminishing its intended advantages. Needless to say that such changes and modifications are within the scope of the attached claims.

1. The way to ensure the patient is suitable for use in a long time probe power, comprising the steps:
providing to a patient in need of long-term enteral nutrition at least once a day over an extended period of time product for enteral feeding through a tube that contains Amigo on 100 kcal of the product:
the protein source;
the source of carbohydrates;
the source of lipids;
sodium from 100 to 200 mg;
potassium from 25 to 250 mg;
the more calcium 50 mg;
phosphorus less than 150 mg;
magnesium, at least 15 mg;
chlorine, at least 100 mg;
iron of 0.4 to 1.5 mg;
zinc from 0.4 to 2.0 mg;
copper from 0.08 to 0.4 mg;
fluorine from 0 to 0.15 mg;
chrome from 2.0 to 10.0 mcg;
molybdenum from 2.0 to 14.0 ág;
selenium from 3.0 to 9.0 µg;
manganese from 0.1 to 0.4 mg;
iodine from 7.0 to 15.0 µg;
vitamin a from 100 to 500 ME;
vitamin D is from 0.5 to 2.5 mcg;
vitamin E from 1.5 to 4.0 mg;
vitamin K is more than 4.0 µg;
vitamin C greater than 4.0 mg;
vitamin B1 than 0.06 mg;
vitamin B2 is more than 0.07 mg;
vitamin B3 from 0.7 to 3.5 mg;
vitamin B5 from 0.2 to 2.0 mg;
vitamin B6 from 0.1 to 0.7 mg;
vitamin B8, at least 1.0 microgram;
vitamin B9, at least to 12.0 µg; and
vitamin B12 from 0.1 to 1.0 μg.

2. The method according to claim 1, in which the product for enteral nutrition contains at least 30 mg of choline per 100 kcal of the product.

3. The method according to claim 1, in which the product for enteral nutrition contains at least 4.0 mg of taurine per 100 kcal of the product.

4. The method according to claim 1, in which the product for enteral nutrition contains at least 3.0 mg of carnitine per 100 kcal of the product.

5. The method according to claim 1, in which:
the protein source provides from 10 to 18% of the energy value of the product;
the source of carbohydrate provides from 40 to 65% energy anotherproduct;
the source of lipids provides from 25 to 40% of the energy value of the product; and the product contains a source of dietary fiber in the amount of at least 10 g/L.

6. The method according to claim 1, in which the product for enteral nutrition contains:
saturated fatty acids in an amount of not more than 1.1 g/100 kcal;
the composition contains between 0.3 and 1.1 g of linoleic acid per 100 kcal;
the composition contains at least 0.06 g of linolenic acid per 100 kcal; and the ratio of n6:n3 is between 2 and 7.

7. The method according to claim 1, wherein the fiber contains insoluble fiber and soluble fiber.

8. The method according to claim 7, in which the insoluble fiber is at least 25% of the source fibers.

9. The method according to claim 1, comprising a prebiotic.

10. The method according to claim 9, which contains prebiotic inulin and/or the Arabian gum.

11. The method according to claim 1, in which the vitamin And at least partially provided by beta-carotene.

12. The method according to claim 1, wherein the fiber contains polysaccharides of soybean and the outer fiber of the peas.

13. The method according to claim 1, containing soluble fiber, insoluble fiber and prebiotic fiber.

14. The method according to claim 1, wherein the product contains a protein source selected from the group consisting of: casein, whey and soy.

15. The method according to 14, in which the protein may be native or partially hydrolyzed.

16. With the royals by 14 in which the product has a density of from 0.8 to 1.4 kcal/ml

17. The method of feeding a patient, comprising the steps:
the provision requiring enteral nutrition to the patient on a long term basis, at least once a day product for enteral nutrition containing:
source of protein, providing from 10 to 18% of the energy value of the product;
the source of carbohydrate that provides from 40 to 65% of the energy value of the product;
the source of lipids, providing from 25 to 40% of the energy value of the product;
source of dietary fiber in the amount of at least 10 g/l, containing
soluble and insoluble fibers;
sodium from 100 to 200 mg;
potassium from 25 to 250 mg;
the more calcium 50 mg;
phosphorus less than 150 mg;
magnesium, at least 15 mg;
chlorine, at least 100 mg;
iron of 0.4 to 1.5 mg;
zinc from 0.4 to 2.0 mg;
copper from 0.08 to 0.4 mg;
fluorine from 0 to 0.15 mg;
chrome from 2.0 to 10.0 mcg;
molybdenum from 2.0 to 14.0 ág;
selenium from 3.0 to 9.0 µg;
manganese from 0.1 to 0.4 mg;
iodine from 7.0 to 15.0 µg;
lycopene at least 0.2 mg;
beta-carotene, at least 0.1 mg;
vitamin a from 100 to 500 ME;
vitamin D is from 0.5 to 2.5 mcg;
vitamin E from 1.5 to 4.0 mg;
vitamin K is more than 4.0 µg;
vitamin C greater than 4.0 mg;
vitamin B1 than 0.06 mg;
vitamin B2 is more than 0.07 mg;
vitamin B3 from 0.7 to 3.5 mg;
vitamin B5 from 0.2 to 2.0 mg;
vitamin B6 from 1 to 0.7 mg;
vitamin B8, at least 1.0 microgram;
vitamin B9, at least to 12.0 µg; and
vitamin B12 from 0.1 to 1.0 μg.

18. The method according to 17, in which the product contains a protein source selected from the group consisting of: casein, whey and soy.

19. The method according to 17, in which the product for enteral nutrition contains at least 30 mg of choline per 100 kcal of the product.

20. The method according to 17, in which the product for enteral nutrition contains at least 4.0 mg of taurine per 100 kcal of the product.

21. The method according to 17, in which the product for enteral nutrition contains at least 3.0 mg of carnitine per 100 kcal of the product.

22. The method according to 17, in which the product for enteral nutrition contains:
saturated fatty acids in an amount of not more than 1.1 g/100 kcal;
the composition contains between 0.3 and 1.1 g of linoleic acid per 100 kcal;
the composition contains at least 0.06 g of linolenic acid per 100 kcal; and the ratio of n6:n3 is between 2 and 7.

23. Product for enteral nutrition containing:
sodium from 100 to 200 mg;
potassium from 25 to 250 mg;
the more calcium 50 mg;
phosphorus less than 150 mg;
magnesium, at least 15 mg;
chlorine, at least 100 mg;
iron of 0.4 to 1.5 mg;
zinc from 0.4 to 2.0 mg;
copper from 0.08 to 0.4 mg;
fluorine from 0 to 0.15 mg;
chrome from 2.0 to 10.0 mcg;
molybdenum from 2.0 to 14.0 ág;
selenium from 3.0 to 9.0 µg;
manganese from 0.1 to 0.4 mg;
yo is from 7.0 to 15.0 μg;
vitamin a from 100 to 500 ME;
vitamin D is from 0.5 to 2.5 mcg;
vitamin E from 1.5 to 4.0 mg;
vitamin K is more than 4.0 µg;
vitamin C greater than 4.0 mg;
vitamin B1 than 0.06 mg;
vitamin B2 is more than 0.07 mg;
vitamin B3 from 0.7 to 3.5 mg;
vitamin B5 from 0.2 to 2.0 mg;
vitamin B6 from 0.1 to 0.7 mg;
vitamin B8, at least 1.0 microgram;
vitamin B9, at least to 12.0 µg;
vitamin B12 from 0.1 to 1.0 µg;
lycopene at least 0.2 mg;
beta-carotene, at least 0.1 mg;
source of protein, providing from 10 to 18% of the energy value of the product;
the source of carbohydrate that provides from 40 to 65% of the energy value of the product;
the source of lipids, providing from 25 to 40% of the energy value of the product; and
source of dietary fiber in the amount of at least 10 g/l, containing both soluble and insoluble fiber.

24. Product for enteral feeding according to item 23, containing at least 30 mg of choline per 100 kcal of the product.

25. Product for enteral feeding according to item 23, containing at least 4.0 mg of taurine per 100 kcal of the product.

26. Product for enteral feeding according to item 23, containing at least 3.0 mg of carnitine per 100 kcal of the product.

27. Product for enteral feeding according to item 23, containing:
saturated fatty acids in an amount of not more than 1.1 g/100 kcal;
the composition contains between 0.3 and 1.1 g of linoleic acid per 100 kcal;
the song contains, at least 0.06 g of linolenic acid per 100 kcal; and the ratio of n6:n3 is between 2 and 7.

28. Product for enteral feeding according to item 23, in which the insoluble fiber is at least 25% of the source fibers.

29. Product for enteral feeding according to item 23, containing a prebiotic.

30. Product for enteral feeding according to item 23, containing a protein source selected from the group consisting of: casein, whey and soy.

31. Product for enteral feeding according to item 23, in which the protein may be native or partially hydrolyzed.



 

Same patents:

FIELD: medicine.

SUBSTANCE: raw material is bracket fungus which is crushed to particle size no more than 0.25 mm, extracted with mixed chloroform and 96 % ethanol (1:2) in the ratio of the raw material to extragent 1:40 for 120 hours, softened by steam at temperature 50-60°C to residual moisture 5 %, dried at temperature 60°C and pressure 0.5 atm to remove chloroform and ethanol completely; the prepared mixture is dissolved in 70 % ethanol in the ratio 1:10.

EFFECT: invention allows implementing said object matter.

2 tbl, 6 ex, 6 dwg

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to pulmonology, and can be used for bronchial tree sanation. That is ensured by the introduction of the superfine aerosol eubiotic 'Sporophthivin' with using an aerosol inhaler.

EFFECT: invention allows effective local sanation from pathogenic germs due to antibacterial and immunomodulating properties of Sporophthivin.

1 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to nephrology, and can be used for treating patients suffering renal insufficiency and especially for treating acute renal insufficiency. Treatment and prevention of acute and chronic renal insufficiency are ensured by the administration of physiologically acceptable lithium salts in physiologic saline in concentration 10-100 mg/ml at lithium salts concentration 0.5-2 mmol/l in blood serum.

EFFECT: ensured treatment and prevention of acute and chronic renal insufficiency.

16 cl, 4 ex, 5 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry and medicine, and aims at wound and burn healing. Described is an analgesic, haemostatic and wound healing agent of the following composition, wt %: polyvinyl pyrrolidone - 2.0-10.0, agar - 1.0-3.0, polyethylene oxide - 1.0-3.0, lidocaine hydrochloride - 0.01-5.0, aminocaproic acid - 0.01-5.0, water - the rest. The agent is prepared by cross-linking of medical polymers when exposed to ionising radiation.

EFFECT: agent exhibits elasticity, tensile strength, wound effluent sorption properties, transparency that allows to follow a wound process course, pain-free removal from a wound surfaces, creates an optimal wound microclimate (humidity, temperature), provides analgesic, haemostatic and wound healing effects.

3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to the field of pharmaceutical industry and medicine and is intended for treatment of wounds and burns. Analgetic and wound healing agent is described, having the following composition, wt %: polyvinylpyrrolidone - 2-10, agar - 1-3, polyethylene oxide - 1-3, lidocaine hydrochloride - 0.01-5.0, water - balance. Agent is produced by linkage of medical-purpose polymers under action of ionising radiation.

EFFECT: agent has elasticity, tensile strength, sorbtion effect relative to wound exudate, transparency, which makes it possible to follow course of wound process, painless removal from wound surface, creates optimal microclimate in wound (humidity, temperature), provides for wound healing and analgetic effects.

3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry and medicine, and aims at wound and burn healing. Described is a haemostatic, antimicrobial and wound healing agent of the following composition, wt %: polyvinyl pyrrolidone - 2.0-10.0, agar - 1.0-3.0, polyethylene oxide - 1.0-3.0, aminocaproic acid - 0.01-1.0, gentamycin - 0.01-1.0, water - the rest. The agent is prepared by cross-linking of medical polymers when exposed to ionising radiation.

EFFECT: agent exhibits elasticity, tensile strength, wound effluent sorption properties, transparency that allows to follow a wound process course, pain-free removal from a wound surfaces, creates an optimal wound microclimate (humidity, temperature), provides haemostatic, antimicrobial and wound healing effects.

3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to medicinal agents and to application of benzoic acid and/or its sodium salt in combination with saccharide (saccharides) as active components to make vaginal composition, to stimulate growing number of gram-positive bacilli and production of acids in vagina, in case gram-positive bacilli in vagina are scarce, and vagina acidity is far too weak, and to inhibit production of acids into vagina, in case of high number of gram-positive bacilli in vagina and excessive acidity of vagina, by maintenance of vaginal secretion pH value in the range from 3.5 to 4.5. Also vaginal composition is described, as well as method to control microflora and acidity of vagina.

EFFECT: development of medicinal agent to stimulate increasing amount of gram-positive bacilli and production of acids in vagina.

13 cl, 3 tbl, 36 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to prophylactic agent for skin, having antituberculous effect, which includes the following active substances - 0.50-0.75 wt % of streptomycin and 7.0-10.0 wt % of stabilised sol of silver nanoparticles, and also polyethylene oxides (PEO) of brands 400 and 1500 as the base.

EFFECT: invention provides a synergetic effect, which shows in ability to suppress antibiotic-resistant strains of microorganisms, including mycobacteria of tuberculosis, and in improvement of bactericide properties of proposed agent.

1 tbl, 5 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: it is proposed to use 3,11b-cis-dihydrotetrabenazine (earlier available for treatment of hyperkinesis) or its pharmaceutically acceptable salt for production of medical agent to prevent or treat inflammatory disease and according method of prophylactics (treatment). It is demonstrated that all stereoisomers of 3,11b-cis-dihydrotetrabenazine are linked to sigma-1- and sigma-2-receptors, modulate production of cytokines by human monocytes, in high concentrations suppress proliferation of T-cells (T-cells are regulators of inflammation in case of a wide range of diseases). In particular, isomer D reduced production of IL-2, IL-4, IL-5, IL-10, IL-12, TNF-α.

EFFECT: production of pharmaceutical composition for production of medicinal agent for prophylactics or treatment of inflammatory disease.

13 cl, 6 dwg, 14 tbl, 9 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: it is proposed to use 3,11b-cis-dihydrotetrabenazine (earlier available for treatment of hyperkinesis) or its pharmaceutically acceptable salt for production of medical agent to prevent or treat inflammatory disease and according method of prophylactics (treatment). It is demonstrated that all stereoisomers of 3,11b-cis-dihydrotetrabenazine are linked to sigma-1- and sigma-2-receptors, modulate production of cytokines by human monocytes, in high concentrations suppress proliferation of T-cells (T-cells are regulators of inflammation in case of a wide range of diseases). In particular, isomer D reduced production of IL-2, IL-4, IL-5, IL-10, IL-12, TNF-α.

EFFECT: production of pharmaceutical composition for production of medicinal agent for prophylactics or treatment of inflammatory disease.

13 cl, 6 dwg, 14 tbl, 9 ex

FIELD: medicine.

SUBSTANCE: invention refers to biotechnology and genetic engineering. DNA is delivered to macroorganism in biocompatible and biodegradable microcapsules made of multilayer polymeric DEAE-dextrane/k-carrageenan membranes protecting DNA from nuclease splitting while delivered to organism cells. Plasmid DNA is sorbed with porous particles CaCO3 by coprecipitating process. The multilayer membranes are produced by sequential layer of DEAE-dextrane and k-carrageenan on the porous particles CaCO3. The microcapsules are placed in 0.1 M EDTA solution. It is agitated at an intensive rate to dissolve an internal core containing CaCO3. The produced microcapsules are washed with water for three times. They are injected in animal cells.

EFFECT: method increases an amount of sorbed DNA to 96,0-99,1 % and provides greater strength of the microcapsule membrane.

3 tbl, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to medicinal agents and to pharmaceutical composition for prevention or treatment of cardiovascular diseases, including pharmacologically efficient amount of a) daglutril and/or its physiologically compatible salts and b) hydrochlorotiaside or its any physiologically compatible tautomers, salts, solvates or esters. Also application of daglutril in combination with hydrochlorotiaside is described to make medicinal agent for prophylactics or treatment of cardiovascular diseases, as well as set for prophylactics or treatment of cardiovascular diseases.

EFFECT: composition according to invention demonstrates synergetic effect in treatment of cardiovascular diseases.

11 cl, 1 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: hereby is described new method of obtaining highly densified and at least partly but preferably completely or almost completely hydrated ceramic material designed for use in pharmaceutical composition manufacture, in particular for controlled release of one or more therapeutic, prophylactic and/or diagnostic compound. Method includes concomitant hydration and densification stage of biologically resolving and hydrating ceramic material such as calcium sulfate.

EFFECT: invention also belongs to compositions containing such ceramic highly densified material pharmaceutical composition can be used for targeted and controlled prolonged local release of active compounds, eg anticancer remedies, thus minimising side effects' range and gravity due to local concentration's temporally optimised dynamics profile.

77 cl, 8 dwg, 9 ex, 5 tbl

FIELD: medicine.

SUBSTANCE: group of inventions relates to biotechnology. Bacillus thuringiensis strains are deposited in the Microorganisms Collection of the Federal State Research Institution 'State Research Centre for Virology and Biotechnology 'Vector' of Federal Service for Supervision of Consumer Rights Protection and Human Welfare' (FGUN GNC VB 'Vector' of Rospotrebnadzor) under collection No.: B. thuringiensis B-1065 and thuringiensis B-1083. The strains show antiviral and anti-candida activity. The preparations made of a culture liquid and lysates of B. thuringiensis B-1065 and B. thuringiensis B-1083 strains effectively inhibit avian influenza virus A/chicken/Kurgan/05/2005 (A/H5N1) replication and show high activity versus Candida activator - pathogenic Candida albicans 620 strain.

EFFECT: strain enhancement.

2 cl, 7 ex

FIELD: medicine.

SUBSTANCE: invention discloses use of nanoparticles containing a matrix of at least one protein containing at least one anti-tumour active substance for preparing a medicinal agent for treating tumours whose resistance to chematherapeutic agents is associated with hyperexpression of P-glycoprotein, wherein the protein matrix includes at least one anti-tumour active substance which is not covalently bonded to said proteins.

EFFECT: doxorubicin nanoparticles in the disclosed medicinal agent and doxorubicin solution had comparable effect on non-resistant neuroblastoma cells; when resistance arose during therapy with cytostatic doxorubicin nanoparticles, the solution and liposomal preparation of doxorubicin were more effective in the disclosed agent.

4 cl, 2 dwg, 2 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to medicinal agents and combination for treatment of respiratory disease, such as asthma, acute or chronic bronchitis, emphysema, chronic obstructive pulmonary disease (COPD), bronchial hyperreactivity or rhinitis, containing efficient amount of (a) inhibitor PDE4 and efficient amount of (b) antagonist of muscarinic receptors M3, representing (3R)-1-phenethyl-3-(9H-xanthene-9-carbonyloxy)-1-azonibicyclo[2.2.2]octane, in the form of salt with anion X, representing pharmaceutically acceptable anion of mono- or polyvalent acid. Also application of (3R)-1-phenethyl-3-(9H-xanthene-9-carbonyloxy)-1-azonibicyclo[2.2.2]octane and inhibitor PDE4 is disclosed for production of medicinal agent for treatment of respiratory disease.

EFFECT: improved therapeutic effect in treatment of respiratory diseases.

19 cl, 7 ex

FIELD: chemistry; biochemistry.

SUBSTANCE: invention pertains to biotechnology. The Staphylococcus epidermidis bacteria strain is deposited in the collection of the All-Russian State Research Institute for Control, Standardisation and Certification of Veterinary Preparations under registration number BVM-1987. The strain is a producer of staphylolytic enzymic complex which lyses antibiotic-resistant pathogenic strains of staphylococci and is stable during storage.

EFFECT: dry staphylolytic enzymic complex retains its bacteriolytic activity for five years when stored at room temperature.

3 tbl, 8 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to field of pharmaceutics and medicine and concerns method of improvement of pharmakinetic characteristics of peroral medication, directly metabolised by UGT1A1, of formula (I), which includes peroral introduction to mammal, which needs drug treatment, of combination of medication, or its pharmaceutically acceptable salt, and atasanavir, or its pharmaceutically acceptable salt.

EFFECT: improvement of pharmakinetic characteristics of medication.

13 cl, 2 dwg, 14 tbl, 7 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to medications and concerns composition for treatment and prevention of hypertension, which includes nebivolol or its pharmaceutically acceptable salt and angiotensin II receptor blocker (ARB).

EFFECT: composition by invention ensures synergetic effect in treatment of hypertension.

8 cl, 4 dwg, 1 ex

FIELD: medicine.

SUBSTANCE: DNA-aptamer specifically and high-affinity get bound with thrombin and is described by general formula: dRGTGACGTANGGTTGGTGTGGTTGGGGCGTCACR (1) where N is any nucleotide of G, A, T, C line or can be absent; R is a chemical radical of 5'-O-methyl-, 5'O-alkyl, 5'-Oallyl; 3'-O-methyl, 3'O-alkil, 3'-O-allyl or can be absent; d is deoxyribose (oligonucleotide contains deoxyribose in all positions).

EFFECT: invention allows producing DNA-aptamer which high-affinity get bound with thrombin, inhibits fibrin-forming activity of purified thrombin, inhibits thrombin activity in human blood plasma, with prolonging activated partial thromboplasmin time, prothrombin and thrombin time, as well as inhibits thrombin stimulated thrombocyte aggregation mediated by thrombin banding with PAR thrombocyte receptors.

2 cl, 13 dwg, 5 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to gerontology and cardiology and can be used for reduction of pathologically increased biological age (BA) in patients with arterial hypertension (AH) with abdominal obesity (FO) and dyslipidemia. Essence of claimed method lies in the following: to patients administered is complex, that includes hypocaloric diet, calculated in kcal by formula: for women: 18-30 years old - (0.0621 × body weight, kg + 2.0357) × 240; 31-60 years old - (0.0342 × body weight, kg + 3.5377) × 240; over 60 years old - (0.0377 × body weight, kg + 2.7545) × 240; for men: 18-30 years old- (0.0630 × body weight, kg+ 2.8957) × 240; 31-60 years old - (0.0484 × body weight, kg + 3.6534) × 240; over 60 years old - (0.049 × body weight, kg + 2.4587) × 240. Also administered are rationally dosed static and dynamic physical loadings, including morning hygienic gymnastics, preventive medical gymnastics, fractional physical exercises during the day, daily swimming in swimming pool for not less than 60 minutes per day. Also introduced are medications simvastatin 10 mg 1 time before going to bed after meal and lisinopril 10 mg 1 time per day in the morning for not less than 7 weeks.

EFFECT: invention combines application of all components of complex allows to normalise BA within 7 weeks of treatment.

2 ex

Up!